Skip to main content

Table 1 Demographic characteristics before treatment

From: Dipeptidyl peptidase 4 inhibitor linagliptin can decrease the dosage of erythropoiesis-stimulating agents in patients on hemodialysis

  DPP4+ DPP4− P
N 13 16  
Age 70.5 ± 12.4 71.7 ± 10.2 NS
Male 8 11 NS
BMI 21.7 ± 3.1 22.6 ± 4.1 NS
HD duration 6.5 ± 5.5 10.4 ± 6.2 NS
Hb 10.8 ± 0.6 11.0 ± 0.8 NS
Dosage of DA 23.9 ± 21.2 16.1 ± 12.1 NS
ERI 2.28 ± 2.08 1.52 ± 1.19 NS
Albumin 3.6 ± 0.4 3.5 ± 0.3 NS
TSAT 24.2 ± 6.6 28.9 ± 13.5 NS
Ferritin 264.7 ± 334.6 138.8 ± 137.3 NS
hs-CRP 5335 ± 6494 4345 ± 9372 NS
GA 22.1 ± 5.8 25.2 ± 5.8 NS
  1. DA darbepoetin alfa, ERI erythropoiesis-stimulating agent-resistant index, Hb hemoglobin, TSAT transferrin saturation, BMI body mass index, GA glycated albumin